Arkin Holdings

Arkin Holdings, founded by Mori Arkin in 2009 and based in Herzliya Pituach, Israel, is a venture capital investment firm specializing in the healthcare sector. The firm focuses on investing in pharmaceutical, biotechnology, dermatology, and medical device companies, as well as software-based healthcare IT and tech-enabled services. Arkin Holdings aims to empower companies that develop innovative technologies and products addressing unmet medical needs, while also emphasizing cost-saving and revenue-generating potential. The firm leverages its extensive experience and financial resources to manage its portfolio and support the research and development of its holdings, fostering growth and creating new value propositions in the healthcare landscape.

Itai Arkin

Investment Manager

Nir Arkin

CEO

Sam Cronin

Investment Manager and Principal

Alon Lazarus

Biotech Investment Manager

Hani Lerman

CFO

Nadav Shimoni

Head of Digital Health and Managing Director

38 past transactions

Virility Medical

Venture Round in 2022
Virility Medical is focused on developing an innovative intimate skin patch aimed at addressing premature ejaculation. The patch incorporates an electronic module that delivers neuromuscular electrical stimulation through the skin to the surrounding muscles. This method is designed to help men manage and delay the onset of premature ejaculation, effectively treating male sexual dysfunction. By utilizing neuromodulation technology, Virility Medical aims to provide a discreet and effective solution for individuals seeking assistance with this common concern.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Phytolon

Series A in 2022
Phytolon Ltd, located in Misgav, Israel, specializes in the development of technology for producing natural food colorants. Founded in 2000, the company utilizes baker's yeast cells as bio-factories to create these colorants through a fermentation process. Phytolon's innovative approach aims to provide sustainable and natural alternatives for the food and beverage industry, addressing the growing demand for clean-label products.

Rhino Health

Venture Round in 2022
Developer of a federated learning and edge-computing platform designed to allow artificial intelligence (AI) /data-science developers to collaborate without sharing data or compromising data privacy. The company's platform distributed computing technologies AI models can quickly and continuously improve by learning from each new dataset and applying those learnings to the next, without requiring costly and risky data transfers, helping users to accelerate the creation and training of more accurate models that work consistently across different patient populations.

Fu-Gen

Private Equity Round in 2022
Fu-Gen is an entrepreneurial independent power producer and renewable energy investor.

Eleos Health

Series A in 2022
Eleos Health is a developer of a SaaS based tool that track mental health.

Mindspace

Venture Round in 2021
Mindspace Ltd. specializes in providing co-working office spaces, catering to a diverse clientele that includes entrepreneurs, freelancers, startups, and established companies. Founded in 2013 and headquartered in Tel Aviv, Israel, the company operates additional offices in cities such as Herzliya, Warsaw, London, Washington, San Francisco, Berlin, Hamburg, and Munich. Mindspace offers a variety of workspaces, including open areas, private offices, and meeting rooms, as well as event spaces designed for different occasions. With a focus on enhancing employee engagement and community, Mindspace creates beautifully designed environments complemented by personalized services and curated events. The company serves a broad range of customers, from blue-chip enterprises to small and medium-sized businesses, across 31 locations in 16 cities and 7 countries in Europe and the United States.

Eleos Health

Seed Round in 2021
Eleos Health is a developer of a SaaS based tool that track mental health.

Eleos Health

Seed Round in 2021
Eleos Health is a developer of a SaaS based tool that track mental health.

Lendbuzz

Series C in 2021
Lendbuzz Funding, LLC offers car loans to expats and international students. The company does not require Social Security Number (SSN) and provides loans to all visa holders from all nationalities. Its customers include students, international professionals, and other young professionals that have an international credit file. The company provides access and manages its loans through an online platform and data-intensive scoring technology. Lendbuzz Funding, LLC was founded in 2015 and is based in Boston, Massachusetts.

Laguna Health

Seed Round in 2021
Laguna Health is a digital health insurance company that helps people realize their recovery potential. It was founded by Yoni Shtein and Yael Peled Adam in 2020 in Tel Aviv, Tel Aviv, Israel.

Edocate

Seed Round in 2021
EDocate provides a platform for simulation-based learning in which medical professionals can learn to care for long-term diseases. The platform offers virtual patient simulations, gamification, mobile and client access, and interaction through social networks. It tailors it to the learning habits and busy lifestyle of adult learners, with a focus on practice skills and optimized quality of care.

Edocate

Seed Round in 2021
EDocate provides a platform for simulation-based learning in which medical professionals can learn to care for long-term diseases. The platform offers virtual patient simulations, gamification, mobile and client access, and interaction through social networks. It tailors it to the learning habits and busy lifestyle of adult learners, with a focus on practice skills and optimized quality of care.

MedMinder

Private Equity Round in 2021
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile's on MedMinder's website. The company was founded in 2007 and is headquartered in Needham, Massachusetts.

MedMinder

Private Equity Round in 2021
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile's on MedMinder's website. The company was founded in 2007 and is headquartered in Needham, Massachusetts.

Rhino Health

Seed Round in 2021
Developer of a federated learning and edge-computing platform designed to allow artificial intelligence (AI) /data-science developers to collaborate without sharing data or compromising data privacy. The company's platform distributed computing technologies AI models can quickly and continuously improve by learning from each new dataset and applying those learnings to the next, without requiring costly and risky data transfers, helping users to accelerate the creation and training of more accurate models that work consistently across different patient populations.

Rhino Health

Seed Round in 2021
Developer of a federated learning and edge-computing platform designed to allow artificial intelligence (AI) /data-science developers to collaborate without sharing data or compromising data privacy. The company's platform distributed computing technologies AI models can quickly and continuously improve by learning from each new dataset and applying those learnings to the next, without requiring costly and risky data transfers, helping users to accelerate the creation and training of more accurate models that work consistently across different patient populations.

Auron Therapeutics

Seed Round in 2021
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

BioSight

Series C in 2020
BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.

Percepto

Series B in 2020
Percepto is a developer of autonomous drone technology for inspection and surveillance. Drones hold the potential to disrupt multi-billion dollar industries including energy, security, insurance, agriculture, and more. Drones completely change the way inspection, measurement, surveillance, and deliveries are done today. Still, the main barrier to making them a must-have platform is the ability of drones to perform tasks autonomously. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the most deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring) the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Pixellot

Series C in 2020
Pixellot is a sports media company based in Tel Aviv, Israel, specializing in automated production solutions for amateur and semi-professional sports. Founded in 2013 by experts in video and media technology, Pixellot offers a patented unmanned multi-camera system that provides comprehensive coverage of sports events, using advanced algorithms for dynamic play analysis and highlight generation. The company streams over 11,000 live video hours monthly to fans, players, and coaches across various platforms. With over 2,000 systems sold globally, Pixellot serves minor leagues, high schools, youth academies, and top clubs, including Bayern Munich and Real Sociedad. Notable partners include ESPN, PlayOn Sports, Sporttotal.tv, and STATS, among others, facilitating extensive reach in the sports media landscape.

Redpin Therapeutics

Series A in 2020
Redpin Therapeutics, Inc., gene therapy company, develops a chemo genetics platform for targeted cell therapies that address intractable diseases of the nervous system. It discovers and develops an ion channel-based chemo genetics platform that enables targeted cell activation/inhibition controlled by low doses of the anti-smoking drug Varenicline. Redpin Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

BioSight

Series C in 2020
BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.

Keros Therapeutics

Series C in 2020
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.

Metabomed

Series B in 2019
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.

Werewolf Therapeutics

Series A in 2019
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Established in 2017, the company is advancing a pipeline of transformative biotherapeutics aimed at treating cancer. Werewolf Therapeutics creates medicines intended for systemic delivery that remain inactive within the body until they arrive at the tumor microenvironment. At this point, the treatments activate to stimulate a robust immune response, thereby targeting and attacking cancer cells effectively.

Pi Therapeutics

Series B in 2019
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

Keros Therapeutics

Series B in 2019
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.

Keros Therapeutics

Series A in 2017
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.

Lendbuzz

Funding Round in 2017
Lendbuzz Funding, LLC offers car loans to expats and international students. The company does not require Social Security Number (SSN) and provides loans to all visa holders from all nationalities. Its customers include students, international professionals, and other young professionals that have an international credit file. The company provides access and manages its loans through an online platform and data-intensive scoring technology. Lendbuzz Funding, LLC was founded in 2015 and is based in Boston, Massachusetts.

ARTSaVIT

Series A in 2017
ARTSaVIT is a biopharmaceuticals company developing a cancer drug.

Digma Medical

Series B in 2016
Digma Medical is a clinical stage medical device company established in 2013, focused on innovating treatments for Type-2 Diabetes and related metabolic syndromes, including NASH. The company is developing the DiaGone™, an endoscopic and disposable device that employs advanced laser technology to treat the duodenum without the need for an implant. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to use the DiaGone™ to enhance the body's ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and other metabolic conditions, thereby improving their overall quality of life and health outcomes. Supported by prominent venture capital firms, Digma Medical is dedicated to advancing effective therapies for diabetes management.

Oncorus

Series A in 2016
Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

BioSight

Venture Round in 2016
BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.

Metabomed

Series A in 2016
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.

Sol-Gel Technologies

Acquisition in 2014
Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.

Quiet Therapeutics

Seed Round in 2013
Quiet Therapeutics Ltd. is a biotechnology company based in Ness Ziona, Israel, that specializes in the discovery and development of cancer therapies. Founded in 2009, the company utilizes its proprietary GAGomer technology, a nanoparticle-based delivery system, to specifically target tumor cells. This innovative approach allows for the delivery of therapeutic agents, including expression plasmids, RNA therapeutics, and small molecules, aimed at inducing the death of cancer cells. By focusing on oncology and inflammation, Quiet Therapeutics aims to expand the range of drug targets and improve treatment outcomes for patients.

cCAM Biotherapeutics

Series A in 2012
cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.